




OTCQB: ONCX



**Breakthrough technology for
women's cancers...**

Corporate Presentation

July 2018

Safe Harbor

Certain of the statements and the projections set forth in this presentation constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including but not limited to the factors set forth in the Risk Factors section of this presentation and to the particular risks inherent in any development stage company that has developed new products for which it has not yet demonstrated market acceptance or generated any historical sales.

Prospective investors are cautioned that there also can be no assurance that the forward-looking statements included in this presentation will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by us or any other person that our objectives and plans will be achieved in any specified timeframe, if at all. Except to the extent required by applicable laws or rules, we do not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

How can I make money with ONCX?

- **Current low valuation <\$10 million**
 - Typical Phase I cancer companies with no revenues with novel drug are \$60-\$100 million

- **Significant upcoming milestones that should drive value**
 - New world-class board members (COMPLETED)
 - Data relating to treatment of mid-dose patients in ovarian trial
 - Formation of scientific and medical advisory board with world leaders
 - Asian partners in China and Japan
 - Acquisition of second drug/technology
 - Completion of Phase 1 ovarian cancer trial
 - Initiation of Phase 2 ovarian cancer trial

Milestones

- ✓ Change name to Oncolix
- ✓ FINRA due diligence
- ✓ Change ticker to ONCX
- ✓ SEC filings
- ✓ Add 2nd independent board member
- ✓ Filing for OTC-QB
- ✓ Acceptance OTC-QB
- ✓ Fiscal year filings (and 1st and 2nd qtr 10Q 2018)
- ✓ \$1 million closing with existing Noteholders
- ❑ Up to \$5 million closing with new investors
- ✓ Add 3rd independent board member
- ❑ Announcement of clinical/scientific advisors
- ❑ News flow relating to ovarian cancer trial
- ❑ Acquisition of new technology
- ❑ Announcement of Asian partner/s

Emerging Clinical-Stage Biotech Company

Clinical Stage Asset

- Prolanta™: prolactin receptor antagonist
- Prolactin plays role in all gynecological cancers
- Dual mechanism of action
- Phase 1 ovarian cancer trial underway
- Orphan Drug status for ovarian cancer
- Robust IP: 8 issued U.S. and foreign patents

Upcoming Milestones

- Phase 1 monotherapy ovarian cancer trial – low dose completed, mid dose in progress
- Phase 1/2a combination trial – initiation in 2018

Emerging Company

- Advancing Prolanta™ into other cancer indications
- Completed reverse merger and raised \$4M in convertible debt
- Publicly-traded under **(ONCX) since 11-29-17**
- Building internal infrastructure: BOD additions, expand clinical and regulatory team, expanding pipeline

Leadership

Experienced management team


Prolanta™: First in Class Prolactin Antagonist

Recombinant protein analog of human prolactin that inhibits prolactin-induced oncogenic signaling

Single amino acid mutation which prevents the activation of the prolactin receptor

- Arginine replaces glycine at sequence 129
- Binds one receptor but not the second, preventing dimerization and resulting in disruption of relevant signaling pathways

Subcutaneous injection packaged as lyophilized protein



Phase 1 clinical trial for ovarian cancer underway

Prolactin Plays Significant Role in Women's Cancers


- **Over-expressed Prolactin receptor** found in many cancers

| | |
|--------------|-----|
| Ovarian: | 80% |
| Breast: | 90% |
| Endometrial: | 80% |

- **Elevated prolactin levels** are found in women's cancers and contributes to pathogenesis of gynecologic malignances
- **Involved in cell proliferation signaling** (JAK/STAT5, Ras/Raf/MAPK and other pathways)
- **Implicated in chemotherapy resistance** (Glutathione-S-transferase (GST) downregulation)
- **Autocrine/paracrine effect** evident in many cancers


Prolanta's Mechanisms of Action

Programmed cell death: Autophagy



1. Prolactin activates Jak2 resulting in cell proliferation
2. Cell signal inducing autophagy
3. Formation of double-membrane vesicle (autophagosome)
4. Fuse with lysosome (autophagolysosome)
5. Cell death

Downregulate GST



- Prolactin induces production of GST which detoxifies platinum drugs (Pt) by removing them from the cell
- Downregulating GST potentially prevents chemoresistance

Ovarian Cancer: Significant Medical Need

4th leading cause of cancer-related death in U.S. women

- Patients typically diagnosed with advanced disease
- Standard of care chemotherapy works but patients eventually relapse

Clear regulatory pathway in platinum resistant ovarian cancer

- Unmet medical need opens up FDA accelerated approval opportunity
- Shorter and less expensive clinical trials
- Less competition for patients
- Potential for 1st line therapy

Enhanced partnering opportunity due to higher incidence of ovarian cancer in EU

Prolanta in Phase 1 trial in recurrent/persistent ovarian cancer

- Scalable cGMP manufacturing process with reproducibility across multiple lots
- Toxicity/Toxicokinetic Data
 - Cynomolgus monkey and rabbit studies performed
 - No significant adverse effects noted

\$1 Billion Annual Opportunity: U.S. Ovarian Cancer Market

Assumption:
\$40,000 per patient

US
Incidence
22,240
Per Year*

US
Prevalence
188,000*

**Sensitive to Chemo
>6 mos. 25%**

**5,505 Patients
\$220 Million**

**Resistant to Chemo
< 6 mos. 25%**

**5,506 Patients
\$220 Million**

**Refractory or cannot
tolerate Chemo
27%**


**5,929 Patients
\$237 Million**

**Diagnosed early or
unstaged
23%**

**5,060 Patients
\$0**

**Recurrent—From
prior years**


**10,000 Patients
\$400 Million**




*Source: National Cancer Institute, 2017

Data Demonstrate Potential Efficacy in Ovarian Cancer

Reduces size and number of tumors




Synergistic with taxanes



Source: MD Anderson Cancer Center

Prolanta shows evidence of synergistic effect in breast cancer models



Each value is a mean ± SD of 6-8 mice/group


** P < 0.01 and * P < 0.05 versus control
 † P < 0.05 versus Herceptin alone

Prolanta alone

Prolanta + Herceptin

Prolanta (G129R) was effective as a monotherapy in a breast cancer model, and was synergistic with Herceptin.

Clinical Development Plan for Ovarian Cancer



Opportunities in Other Women's Cancers

| Product | Indication | Research | Mfg Optimization | Pre-clinical | Phase I | Phase IIa | Phase IIb |
|------------------|-------------------------------|---|------------------|--------------|---------|-------------|-------------|
| Prolanta™ | Ovarian Cancer | | | | | N/A | N/A |
| Prolanta™ | Ovarian/ Combo Therapy | | | | | 2019 | 2020 |
| Prolanta™ | Uterine Cancer* | | | | | 2019 | 2020 |
| Prolanta™ | Breast Cancer | To be pursued with a pharmaceutical partner or post-approval of ovarian indication | | | | | |

*currently under evaluation at MD Anderson

Financing History

| | |
|--|---|
| Greenville Hospital System (GHS) | \$7.7 million |
| BioVectra (PIK) | \$1.5 million |
| Emerging Technology Fund | \$3.9 million |
| Clinical Accelerator (10% PIK) | \$0.05 million |
| Convertible Notes Family offices Accredited Investors | \$3.7 million |
| Current Financing Closed June 2018 | \$1+ million Current Noteholders |
| New Financing In Progress | \$2-6 Million |

Capital Requirements

- Expanded Clinical and Regulatory Involvement
- Expanded sponsored research at MD Anderson to uterine cancer
- **Acquisition of new cancer asset**
 - **New focus will be women's and pediatric cancers**
 - **Multiple licensing candidates in due diligence**

\$29.9 million capital raise to fund ovarian cancer trials through Phase IIb trial results (monotherapy) and combination with chemotherapy trials through Phase 2b (does not include new disease indications for Prolanta or a new acquisition)

Capital Requirements Through Phase 2b

| <u>2018</u> | <u>2019</u> | <u>2020</u> |
|----------------|---------------|----------------|
| \$ 3.0M | \$9.1M | \$17.8M |

Experienced Management Team



Michael Redman, CEO, BOD

- Formerly CEO of Bone Medical, CEO and founder of Opexa Pharmaceuticals; VP, Corporate Development, Aronex Pharmaceuticals; VP, Business Development, Repros Therapeutics
- Extensive Licensing and acquisition experience; Phase I through III clinical trial management
- Author of successful grant /award applications



Donald Payne, Senior Vice President

- Formerly CFO of Sensus Drug and LifeCell Corporation; founding CEO of Nanospectra Biosciences
- Extensive finance, corporate governance, technical writing, clinical trial and audit experience
- Author of successful grant/award applications; co-inventor of two patents



Jerry Youkey, MD, Chairman of BOD

- Dean, U of SC Medical School
- VP, Greenville Hospital System



Dale Zajicek, BOD

- Former president, BioVectra
- Expert in manufacturing



John Holaday, PhD

- CEO and co-founder of QRx Pharma, Entremed, Maxcyte, Medicis
- 90 patents
- 230 scientific articles



Sherry Grisewood, CFA

- TapImmune
- Dawson James
- Jesup and Lamont Securities

Scientific and Clinical Advisory Board

First member(s) to be announced in July 2018

Other Advisors:

William Gannon, MD, Chief Regulatory Officer

- Numerous managerial experience with multinational CROs, biotech and pharmaceutical companies, primarily cancer
- Substantial regulatory submissions and execution of Phase I through Phase IV both US and international

Anil Sood, MD

- Professor & Director, Blanton-Davis Ovarian Cancer Research Program, MD Anderson Cancer Center
- Discovered Prolanta's mechanism of action (Autophagy)
- Preclinical efficacy and biomarker evaluation of Prolanta

Compelling Opportunity

Investment Highlights

- ✓ **Clinical stage oncology asset**, Prolanta™, is a first-in-class prolactin antagonist currently in Phase 1 for ovarian cancer
- ✓ **FDA designated Prolanta™** as an Orphan Drug in ovarian cancer
- ✓ **Serves an unmet clinical** need as patients treated with standard of care chemotherapy eventually relapse and no viable alternative
- ✓ **Large market opportunity** with a \$1B US ovarian cancer market
- ✓ **Prolactin plays a role in cancer** in women, making Prolanta™ a valuable drug candidate to advance in other cancer indications

Upcoming Milestones

- ✓ Merge with AEPP with \$2 million new capital raise as AEPP OTC-Pink **(Aug 2017)**
- ✓ Name change from AEPP to Oncolix **(Nov 2017)**
- ✓ New stock exchange symbol ONCX **(Nov 2017)**
- ✓ 2nd Independent board member **(Dec 2017)**
- ✓ File for uplisting to OTCQB **(Dec 2017)**
- ✓ Uplist from Pink Sheets to OTCQB **(Dec 2017)**
- ✓ Phase 1 Mid Dose patients **(Jan 2018)**
- ✓ Form Clinical/Scientific Advisory Board
- ❑ Acquire New Technology (soon)
- ❑ Second capital raise
- ❑ Prolanta monotherapy Phase 1 ovarian cancer interim data and trial completion
- ❑ Asian Licensing and Development Collaboration for Prolanta
- ❑ Initiate Prolanta Phase 2 (combo with chemo) in ovarian cancer
- ❑ 2018 Capital Raise to fund Phase 2 ovarian trials and new technology

A woman with dark hair tied back, wearing a white long-sleeved top and white pants, is sitting in a meditative pose on a sandy beach. Her arms are raised and extended outwards, palms facing up. She has her eyes closed and a serene expression. The background shows a clear blue sky with light clouds, a turquoise ocean with white waves, and a sandy beach. The overall scene is peaceful and bright.

Thank You
Oncolix